Jemincare Group, founded in 1999, is a comprehensive large health industry group with more than 12,000 employees. Headquartered in Nanchang, Jiangxi, it has established industrial platforms and R&D institutions in Jiangxi, Beijing, Shanghai, Jiangsu, Zhejiang and other places. In 2019, the group's operating revenue exceeded 35.8 billion yuan, and it was selected into the Xinhua News Agency National Brand Project, ranking among the top ten of China's top 100 pharmaceutical industry for many consecutive years.
Wuxi Jiyu Shanhe Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Jiangxi Jemincare Group. The company is located at No. 12 Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province. Adhering to the working philosophy of "cherish life, produce with heart" and relying on advanced technology and talent teams, the company currently has 15 dosage forms including large and small volume injections, eye drops, nasal drops, pills, and tablets, 206 drug production approvals, and 55 patents. Product quality and efficacy enjoy widespread quality reputation and market recognition among similar domestic products.
To meet market demand and the needs of new product R&D and implementation, the group plans to build Shanhe Pharmaceutical into a production platform for small-volume injections and high-end formulations. Under the leadership of the group, Shanhe Pharmaceutical will continue to develop and innovate, striving to become a modern pharmaceutical enterprise that is "first-class in China and internationally aligned".
High-end formulation project under construction: the total investment in the new drug project is approximately 1 billion yuan. The project will undertake high-end formulation projects from the Shanghai Research Institute in core key medical fields. It mainly includes: liposomal injections, inhaled nasal sprays, inhaled nebulized liquids, microsphere long-acting formulations, etc. These products are all high-tech-difficulty and high-value-added products.
Innovative drugs & macromolecular biologics production base project under construction: approved in Wuxi in September 2020, covering an area of 67 mu, with a total investment of approximately 1 billion yuan. The project will build a research center, innovative drug production workshops, administrative office areas, intelligent warehousing, power centers, sewage treatment facilities and other auxiliary facilities. The project is scheduled to be completed and put into operation in 2023, and will mainly be used for the production of innovative drugs for COVID-19 neutralizing antibodies and macromolecular innovative drugs, and will also help more *new biomedical achievements benefit patients in the future.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows